Strides Pharma Science share news and announcements
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Formerly Strides Shasun
Last close ₹1,014.80up ₹16.40 (1.64%)BSE ₹1,012.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹998.40.
52-week range of traded prices to 23 Oct 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹9,354 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 15.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.49%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 21.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,12,38541.2% delivered
Strides Pharma Science share news and announcements
1,456 announcements, routine notices left out, newest first. Page 24 of 30.
May 2011
12 May · Dividend
Dividend payout date will be June 08, 2011, subject to the approval of dividends by the shareholders of the Company at the ensuing Annual General Meeting on May 30, 2011.4 May · Meeting
Register of Members and Transfer Books of the Company will remain closed from May 20, 2011 to May 30, 2011 (both days inclusive), in connection with the Annual General Meeting of the Company convened to be held on May 30, 2011 and for the purpose of payment of dividend on equity shares for the year ended December 31, 2010, if declared and authorized at the ensuing AGM of the Company.
Apr 2011
25 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2011 as follows: Net Sales of Rs. 12719.61 lacs for quarter ending on 31-MAR-2011 against Rs. 13138.78 lacs for the quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 1274.3 lacs for the quarter ending on 31-MAR-2011 against Rs. 1006.45 lacs for the quarter ending on 31-MAR-2010.25 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2011 as follows: Net Sales of Rs. 48747.71 lacs for quarter ending on 31-MAR-2011 against Rs. 37355.06 lacs for the quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 4070.56 lacs for the quarter ending on 31-MAR-2011 against Rs. 3983.01 lacs for the quarter ending on 31-MAR-2010.20 Apr · Business
Company has allotted 75,000 fully paid equity shares of Rs.10/- each under Strides Arcolab ESOP 2008 (Directors) Scheme to Non-Executive Directors of the Company. Consequent to the allotment, the paid up equity share capital of the Company has increased from Rs. 579,491,710.00 consisting of 57,949,171 equity shares of Rs.10/- each to Rs. 580,241,710.00 consisting of 58,024,171 equity shares of Rs.10/- each.18 Apr · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended March 31, 2011.8 Apr · Business
Company has allotted 180,000 fully paid equity shares of Rs.10/- each under the Strides Arcolab ESOP 2006 and ESOP 2008 Schemes. Consequent to the allotment, the paid up equity share capital of the Company has increased from Rs. 577,691,710 consisting of 57,769,171 equity shares of Rs.10/- each to Rs. 579,491,710 consisting of 57,949,171 equity shares of Rs.10/- each.7 Apr · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Strides Arcolab Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Strides Arcolab Limited has vide its letter inter-alia stated,"We wish to clarify that there are no material events / price sensitive information/announcement (including pending announcement) which the Company has not disclosed to the exchange."
Mar 2011
7 Mar · Business
Strides Arcolab Limited had informed the Exchange that the Company has allotted 24,500 fully paid equity shares of Rs.10/- each on conversion of employee stock options under Strides Arcolab ESOP 2008 Scheme. Consequent to the above allotment, the paid up equity share capital of the Company has increased from Rs.577,446,710.00 consisting of 57,744,671 equity shares of Rs.10/- each to Rs.577,691,710.00 consisting of 57,769,671 equity shares of Rs.10/- each. The Company has now informed the Exchange that consequent to the allotment of 24,500 equity shares on conversion of employee stock options, the paid up capital of the Company is Rs.577,691,710.00 consisting of 57,769,171 equity shares (insteads of 57,769,671 equity shares as mentioned in earlier letter).1 Mar · Business
Company has allotted 24,500 fully paid equity shares of Rs.10/- each on conversion of employee stock options under Strides Arcolab ESOP 2008 Scheme. Consequent to the above allotment, the paid up equity share capital of the Company has increased from Rs.577,446,710.00 consisting of 57,744,671 equity shares of Rs.10/- each to Rs.577,691,710.00 consisting of 57,769,671 equity shares of Rs.10/- each.
Feb 2011
24 Feb · Results
Consolidated Results for the year ended on 31-DEC-2010 as follows: Net Sales of Rs. 169584.41 lacs for year ending on 31-DEC-2010 against Rs. 130477.14 lacs for the year ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 12244.75 lacs for the year ending on 31-DEC-2010 against Rs. 10968.39 lacs for the year ending on 31-DEC-2009.24 Feb · Dividend
Board of Directors of the Company at its meeting held on February 24, 2011 has recommended dividend at 15% viz., Rs 1.50 per share for the year ended December 31, 2010.24 Feb · Results
Standalone Results for the year ended on 31-DEC-2010 as follows: Net Sales of Rs. 50463.77 lacs for year ending on 31-DEC-2010 against Rs. 76944.2 lacs for the year ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 7356.08 lacs for the year ending on 31-DEC-2010 against Rs. 10551.43 lacs for the year ending on 31-DEC-2009.11 Feb · Board meeting
To consider inter-alia, the audited financial results of the Company for the financial year ended December 31, 2010 and recommendation of dividend, if any.9 Feb · Disclosure
Compensation Committee of the Company has granted an aggregate of 680,500 options to eligible employees under the Strides Arcolab ESOP 2006 and Strides Arcolab ESOP 2008 Schemes at an exercise price Rs.331.15 per option. The shares covered by such options are 680,500 shares. The vesting period of these options is in a phased manner over a period of 3 years. The options may be exercised within a period of 30 days from the date of vesting.
Jan 2011
Dec 2010
22 Dec · Meeting
Based on the Scrutinizer's Report dated December 21, 2010 the resolution seeking approval of the shareholders through Postal Ballot concerning Amendment in Articles of Association of the Company has been passed with requisite majority.
Nov 2010
19 Nov · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended September 30,2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Nov · Business
Company has allotted 40,000 fully paid equity shares of Rs.10/- each under Strides Arcolab ESOP 2006 Scheme. Consequent to the allotment, the paid up equity share capital of the Company has increased from Rs.577,046,710 consisting of 57,704,671 equity shares of Rs.10/- each to Rs.577,446,710 consisting of 57,744,671 equity shares of Rs.10/- each.
Oct 2010
27 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 12672.08 lacs for quarter ending on 30-SEP-2010 against Rs. 16578.79 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 1065.21 lacs for the quarter ending on 30-SEP-2010 against Rs. 423.25 lacs for the quarter ending on 30-SEP-2009.27 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 41219.27 lacs for quarter ending on 30-SEP-2010 against Rs. 31714.42 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 3457.65 lacs for the quarter ending on 30-SEP-2010 against Rs. 1973.38 lacs for the quarter ending on 30-SEP-2009.19 Oct · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended September 30, 2010.15 Oct · Management
Dr. Ronald Ling, a non executive director on the Board of the Company has resigned from the company with effect from October 14, 2010.5 Oct · Business
Company has allotted 41,000 fully paid equity shares of Rs.10/- each on conversion of Employee Stock Options under Strides Arcolab ESOP 2008 Scheme. Consequent to the above allotment, the paid up equity share capital of the Company has increased from Rs.576,636,710.00 consisting of 57,663,671 equity shares of Rs.10/- each to Rs.577,046,710 consisting of 57,704,671 equity shares of Rs.10/- each.